Natural killer cell biology: An update and future directions

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 3, 2013, Pages 536-544

  Campbell, Kerry S ^a   Hasegawa, Jun ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

antibody dependent cellular cytotoxicity; cancer viral infection hematopoietic stem cell transplantation; IFN ; immune memory; immunomodulatory drugs; innate immunity; killer cell immunoglobulin like receptors; Natural killer cell

Indexed keywords

ADAPTIVE IMMUNITY; CANCER PATIENT; CELL MATURATION; CYTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACUTE MYELOID LEUKEMIA; ADCC; AML; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; CANCER; CAR; CHIMERIC ANTIGEN RECEPTOR; CLASS I MHC; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HSC; IFN-Γ; ILC; IMMUNE MEMORY; IMMUNOMODULATORY DRUGS; IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIF; INNATE IMMUNITY; INNATE LYMPHOID CELL; ITIM; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS; KIR; MCMV; MHC-I; MM; MOUSE CYTOMEGALOVIRUS; MULTIPLE MYELOMA; NATURAL CYTOTOXICITY RECEPTOR; NATURAL KILLER; NATURAL KILLER CELL; NCR; NK; PD-1; PROGRAMMED CELL DEATH 1; SELF-RECOGNIZING INHIBITORY RECEPTOR; SRIR; VIRAL INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; RECEPTORS, NATURAL KILLER CELL;

EID: 84883244752     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.07.006     Document Type: Review

References (115)

1. C. Fauriat, E.O. Long, H.G. Ljunggren, and Y.T. Bryceson Regulation of human NK-cell cytokine and chemokine production by target cell recognition Blood 115 2010 2167 2176
2. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini Functions of natural killer cells Nat Immunol 9 2008 503 510
3. S.N. Waggoner, M. Cornberg, L.K. Selin, and R.M. Welsh Natural killer cells act as rheostats modulating antiviral T cells Nature 481 2012 394 398
4. S. Schuster, B. Hurrell, and F. Tacchini-Cottier Crosstalk between neutrophils and dendritic cells: a context-dependent process J Leukoc Biol 2012 [Epub ahead of print]
5. R. Wehner, K. Dietze, M. Bachmann, and M. Schmitz The bidirectional crosstalk between human dendritic cells and natural killer cells J Innate Immun 3 2011 258 263
6. H. Spits, D. Artis, M. Colonna, A. Diefenbach, J.P. Di Santo, and G. Eberl Innate lymphoid cells - a proposal for uniform nomenclature Nat Rev Immunol 13 2013 145 149
7. J.A. Walker, J.L. Barlow, and A.N. McKenzie Innate lymphoid cells - how did we miss them? Nat Rev Immunol 13 2013 75 87
8. M.A. Caligiuri Human natural killer cells Blood 112 2008 461 469
9. bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL-2: a potential new link between adaptive and innate immunity Blood 101 2003 3052 3057
10. H1 priming Nat Immunol 5 2004 1260 1265
11. M. Fang, F. Roscoe, and L.J. Sigal Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking J Exp Med 207 2010 2369 2381
12. + NK cells as rapid producers of abundant IFN-gamma on activation Proc Natl Acad Sci U S A 108 2011 728 732
13. dim NK cells to respond to pathogen-associated signals J Immunol 182 2009 6426 6434
14. J. Zhang, Z. Chen, G.N. Smith, and B.A. Croy Natural killer cell-triggered vascular transformation: maternal care before birth? Cell Mol Immunol 8 2011 1 11
15. J.S. Orange Human natural killer cell deficiencies Curr Opin Allergy Clin Immunol 6 2006 399 409
16. H.G. Ljunggren, and K. Kärre In search of the "missing self": MHC molecules and NK cell recognition Immunol Today 11 1990 237 244
17. D. Horst, M.C. Verweij, A.J. Davison, M.E. Ressing, and E.J. Wiertz Viral evasion of T cell immunity: ancient mechanisms offering new applications Curr Opin Immunol 23 2011 96 103
18. B. Seliger, U. Ritz, and S. Ferrone Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation Int J Cancer 118 2006 129 138
19. K. Krzewski, and J.E. Coligan Human NK cell lytic granules and regulation of their exocytosis Front Immunol 3 2012 335
20. A.W. MacFarlane 4th, and K.S. Campbell Signal transduction in natural killer cells Curr Top Microbiol Immunol 298 2006 23 57
21. F. Cichocki, T. Lenvik, N. Sharma, G. Yun, S.K. Anderson, and J.S. Miller Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-Like RNA in human NK Cells J Immunol 185 2010 2009 2012
22. G.E. Davies, S.M. Locke, P.W. Wright, H. Li, R.J. Hanson, and J.S. Miller Identification of bidirectional promoters in the human KIR genes Genes Immun 8 2007 245 253
23. A. Saleh, G.E. Davies, V. Pascal, P.W. Wright, D.L. Hodge, and E.H. Cho Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation Immunity 21 2004 55 66
24. P. Parham MHC class I molecules and KIRs in human history, health and survival Nat Rev Immunol 5 2005 201 214
25. S.K. Anderson, J.R. Ortaldo, and D.W. McVicar The ever-expanding Ly49 gene family: repertoire and signaling Immunol Rev 181 2001 79 89
26. C. Vilches, and P. Parham KIR: diverse, rapidly evolving receptors of innate and adaptive immunity Annu Rev Immunol 20 2002 217 251
27. L.L. Lanier Up on the tightrope: natural killer cell activation and inhibition Nat Immunol 9 2008 495 502
28. A. Moretta, C. Bottino, M. Vitale, D. Pende, C. Cantoni, and M.C. Mingari Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis Ann Rev Immunol 19 2001 197 223
29. S. Bauer, V. Groh, J. Wu, A. Steinle, J.H. Phillips, and L.L. Lanier Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science 285 1999 727 729
30. C.S. Brandt, M. Baratin, E.C. Yi, J. Kennedy, Z. Gao, and B. Fox The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans J Exp Med 206 2009 1495 1503
31. A.C. Brown, I.M. Dobbie, J.M. Alakoskela, I. Davis, and D.M. Davis Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins Blood 120 2012 3729 3740
32. C.C. Gross, J.A. Brzostowski, D. Liu, and E.O. Long Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization J Immunol 185 2010 2918 2926
33. E.M. Mace, J. Zhang, K.A. Siminovitch, and F. Takei Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells Blood 116 2010 1272 1279
34. T. Hanke, H. Takizawa, and D.H. Raulet MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model Eur J Immunol 31 2001 3370 3379
35. K. Schönberg, M. Sribar, J. Enczmann, J.C. Fischer, and M. Uhrberg Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition Blood 117 2011 98 107
36. N. Anfossi, P. Andre, S. Guia, C.S. Falk, S. Roetynck, and C.A. Stewart Human NK cell education by inhibitory receptors for MHC class I Immunity 25 2006 331 342
37. P. Brodin, T. Lakshmikanth, S. Johansson, K. Karre, and P. Hoglund The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells Blood 113 2009 2434 2441
38. S. Cooley, F. Xiao, M. Pitt, M. Gleason, V. McCullar, and T.L. Bergemann A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature Blood 110 2007 578 586
39. S. Kim, J.B. Sunwoo, L. Yang, T. Choi, Y.J. Song, and A.R. French HLA alleles determine differences in human natural killer cell responsiveness and potency Proc Natl Acad Sci U S A 105 2008 3053 3058
40. D.H. Raulet, and R.E. Vance Self-tolerance of natural killer cells Nat Rev Immunol 6 2006 520 531
41. N.C. Fernandez, E. Treiner, R.E. Vance, A.M. Jamieson, S. Lemieux, and D.H. Raulet A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules Blood 105 2005 4416 4423
42. S. Kim, J. Poursine-Laurent, S.M. Truscott, L. Lybarger, Y.J. Song, and L. Yang Licensing of natural killer cells by host major histocompatibility complex class I molecules Nature 436 2005 709 713
43. D.H. Raulet, W. Held, I. Correa, J.R. Dorfman, M.F. Wu, and L. Corral Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors Immunol Rev 155 1997 41 52
44. N.M. Valiante, M. Uhrberg, H.G. Shilling, K. Lienert-Weidenbach, K.L. Arnett, and A. D'Andrea Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors Immunity 7 1997 739 751
45. H. Furukawa, T. Yabe, K. Watanabe, R. Miyamoto, A. Miki, and T. Akaza Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I) Hum Immunol 60 1999 32 40
46. N.S. Liao, M. Bix, M. Zijlstra, R. Jaenisch, and D. Raulet MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity Science 253 1991 199 202
47. P. Brodin, K. Karre, and P. Hoglund NK cell education: not an on-off switch but a tunable rheostat Trends Immunol 30 2009 143 149
48. N.T. Joncker, N.C. Fernandez, E. Treiner, E. Vivier, and D.H. Raulet NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model J Immunol 182 2009 4572 4580
49. A. Chalifour, L. Scarpellino, J. Back, P. Brodin, E. Devevre, and F. Gros A Role for cis interaction between the inhibitory Ly49A receptor and MHC class I for natural killer cell education Immunity 30 2009 337 347
50. M.T. Orr, W.J. Murphy, and L.L. Lanier 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection Nat Immunol 11 2010 321 327
51. R. Koka, P.R. Burkett, M. Chien, S. Chai, F. Chan, and J.P. Lodolce Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice J Exp Med 197 2003 977 984
52. A.M. Jamieson, P. Isnard, J.R. Dorfman, M.C. Coles, and D.H. Raulet Turnover and proliferation of NK cells in steady state and lymphopenic conditions J Immunol 172 2004 864 870
53. M. Prlic, B.R. Blazar, M.A. Farrar, and S.C. Jameson In vivo survival and homeostatic proliferation of natural killer cells J Exp Med 197 2003 967 976
54. J.C. Sun, J.N. Beilke, N.A. Bezman, and L.L. Lanier Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection J Exp Med 208 2011 357 368
55. J.C. Sun, J.N. Beilke, and L.L. Lanier Adaptive immune features of natural killer cells Nature 457 2009 557 561
56. Y. Hayakawa, and M.J. Smyth CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity J Immunol 176 2006 1517 1524
57. J.C. Sun, S. Madera, N.A. Bezman, J.N. Beilke, M.H. Kaplan, and L.L. Lanier Proinflammatory cytokine signaling required for the generation of natural killer cell memory J Exp Med 209 2012 947 954
58. + natural killer cells with potent function Blood 119 2012 2665 2674
59. hi natural killer cell subset during acute human cytomegalovirus infection Proc Natl Acad Sci U S A 108 2011 14725 14732
60. V. Beziat, L.L. Liu, J.A. Malmberg, M.A. Ivarsson, E. Sohlberg, and A.T. Bjorklund NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs Blood 121 2013 2678 2688
61. N.K. Björkström, T. Lindgren, M. Stoltz, C. Fauriat, M. Braun, and M. Evander Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus J Exp Med 208 2011 13 21
62. M.A. Cooper, J.M. Elliott, P.A. Keyel, L. Yang, J.A. Carrero, and W.M. Yokoyama Cytokine-induced memory-like natural killer cells Proc Natl Acad Sci U S A 106 2009 1915 1919
63. J. Ni, M. Miller, A. Stojanovic, N. Garbi, and A. Cerwenka Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors J Exp Med 209 2012 2351 2365
64. R. Romee, S.E. Schneider, J.W. Leong, J.M. Chase, C.R. Keppel, and R.P. Sullivan Cytokine activation induces human memory-like NK cells Blood 120 2012 4751 4760
65. J.G. O'Leary, M. Goodarzi, D.L. Drayton, and U.H. von Andrian T cell- and B cell-independent adaptive immunity mediated by natural killer cells Nat Immunol 7 2006 507 516
66. S. Paust, H.S. Gill, B.Z. Wang, M.P. Flynn, E.A. Moseman, and B. Senman Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses Nat Immunol 11 2010 1127 1135
67. U.J. Seidel, P. Schlegel, and P. Lang Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Front Immunol 4 2013 76
68. H.E. Kohrt, R. Houot, M.J. Goldstein, K. Weiskopf, A.A. Alizadeh, and J. Brody CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies Blood 117 2011 2423 2432
69. D.M. Benson, C.E. Bakan, A. Mishra, C.C. Hofmeister, Y. Efebera, and B. Becknell The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody Blood 116 2010 2286 2294
70. L. Binyamin, R.K. Alpaugh, T.L. Hughes, C.T. Lutz, K.S. Campbell, and L.M. Weiner Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy J Immunol 180 2008 6392 6401
71. C. Sola, P. Andre, C. Lemmers, N. Fuseri, C. Bonnafous, and M. Blery Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo Proc Natl Acad Sci U S A 106 2009 12879 12884
72. F. Romagne, P. Andre, P. Spee, S. Zahn, N. Anfossi, and L. Gauthier Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells Blood 114 2009 2667 2677
73. D.M. Benson Jr., C.C. Hofmeister, S. Padmanabhan, A. Suvannasankha, S. Jagannath, and R. Abonour A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma Blood 120 2012 4324 4333
74. N. Vey, J.H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet, and A. Charbonnier A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission Blood 120 2012 4317 4323
75. D.M. Benson Jr., C.E. Bakan, S. Zhang, S.M. Collins, J. Liang, and S. Srivastava IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect Blood 118 2011 6387 6391
76. S.I. Khakoo, C.L. Thio, M.P. Martin, C.R. Brooks, X. Gao, and J. Astemborski HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection Science 305 2004 872 874
77. S.E. Hiby, J.J. Walker, K.M. O'Shaughnessy, C.W. Redman, M. Carrington, and J. Trowsdale Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success J Exp Med 200 2004 957 965
78. G.M. O'Connor, E. Yamada, A. Rampersaud, R. Thomas, M. Carrington, and D.W. McVicar Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1 J Immunol 187 2011 2162 2171
79. J.P. Vivian, R.C. Duncan, R. Berry, G.M. O'Connor, H.H. Reid, and T. Beddoe Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B Nature 479 2011 401 405
80. M.P. Martin, X. Gao, J.H. Lee, G.W. Nelson, R. Detels, and J.J. Goedert Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS Nat Genet 31 2002 429 434
81. M.P. Martin, Y. Qi, X. Gao, E. Yamada, J.N. Martin, and F. Pereyra Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 Nat Genet 39 2007 733 740
82. K. Pelak, A.C. Need, J. Fellay, K.V. Shianna, S. Feng, and T.J. Urban Copy number variation of KIR genes influences HIV-1 control PLoS Biol 9 2011 e1001208
83. A. Velardi, and L. Ruggeri Alessandro, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation Trends Immunol 23 2002 438
84. L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W.D. Shlomchik, and A. Tosti Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
85. L. Ruggeri, M. Capanni, M. Casucci, I. Volpi, A. Tosti, and K. Perruccio Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 94 1999 333 339
86. J.S. Miller, S. Cooley, P. Parham, S.S. Farag, M.R. Verneris, and K.L. McQueen Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood 109 2007 5058 5061
87. K.C. Hsu, C. Pinto-Agnello, T. Gooley, M. Malkki, B. Dupont, and E.W. Petersdorf Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component Tissue Antigens 69 suppl 1 2007 42 45
88. K.L. McQueen, K.M. Dorighi, L.A. Guethlein, R. Wong, B. Sanjanwala, and P. Parham Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation Hum Immunol 68 2007 309 323
89. S. Cooley, D.J. Weisdorf, L.A. Guethlein, J.P. Klein, T. Wang, and C.T. Le Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia Blood 116 2010 2411 2419
90. K. Stringaris, S. Adams, M. Uribe, R. Eniafe, C.O. Wu, and B.N. Savani Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies Biol Blood Marrow Transplant 16 2010 1257 1264
91. J.M. Venstrom, G. Pittari, T.A. Gooley, J.H. Chewning, S. Spellman, and M. Haagenson HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1 N Engl J Med 367 2012 805 816
92. P. Haas, P. Loiseau, R. Tamouza, J.M. Cayuela, H. Moins-Teisserenc, and M. Busson NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation Blood 117 2011 1021 1029
93. J.S. Miller, Y. Soignier, A. Panoskaltsis-Mortari, S.A. McNearney, G.H. Yun, and S.K. Fautsch Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 2005 3051 3057
94. J.E. Rubnitz, H. Inaba, R.C. Ribeiro, S. Pounds, B. Rooney, and T. Bell NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 2010 955 959
95. A. Curti, L. Ruggeri, A. D'Addio, A. Bontadini, E. Dan, and M.R. Motta Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients Blood 118 2011 3273 3279
96. S.A. Koepsell, J.S. Miller, and D.H. McKenna Jr. Natural killer cells: a review of manufacturing and clinical utility Transfusion 53 2013 404 410
97. H. Klingemann, C. Grodman, E. Cutler, M. Duque, D. Kadidlo, and A.K. Klein Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions Transfusion 53 2013 412 418 quiz 411
98. J.N. Kochenderfer, M.E. Dudley, S.A. Feldman, W.H. Wilson, D.E. Spaner, and I. Maric B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
99. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
100. R.J. Brentjens, I. Riviere, J.H. Park, M.L. Davila, X. Wang, and J. Stefanski Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 2011 4817 4828
101. B. Altvater, S. Landmeier, S. Pscherer, J. Temme, K. Schweer, and S. Kailayangiri 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells Clin Cancer Res 15 2009 4857 4866
102. C. Imai, S. Iwamoto, and D. Campana Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood 106 2005 376 383
103. L. Li, L.N. Liu, S. Feller, C. Allen, R. Shivakumar, and J. Fratantoni Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method Cancer Gene Ther 17 2010 147 154
104. C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, and H.G. Klingemann Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood 100 2002 1265 1273
105. T. Muller, C. Uherek, G. Maki, K.U. Chow, A. Schimpf, and H.G. Klingemann Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells Cancer Immunol Immunother 57 2008 411 423
106. S. Arai, R. Meagher, M. Swearingen, H. Myint, E. Rich, and J. Martinson Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial Cytotherapy 10 2008 625 632
107. J.M. McDaniel, J. Pinilla-Ibarz, and P.K. Epling-Burnette Molecular action of lenalidomide in lymphocytes and hematologic malignancies Adv Hematol 2012 2012 513702
108. D. Zhu, L.G. Corral, Y.W. Fleming, and B. Stein Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation Cancer Immunol Immunother 57 2008 1849 1859
109. T. Hayashi, T. Hideshima, M. Akiyama, K. Podar, H. Yasui, and N. Raje Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application Br J Haematol 128 2005 192 203
110. A.K. Hsu, H. Quach, T. Tai, H.M. Prince, S.J. Harrison, and J.A. Trapani The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy Blood 117 2011 1605 1613
111. D. Chen, M. Frezza, S. Schmitt, J. Kanwar, and Q.P. Dou Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives Curr Cancer Drug Targets 11 2011 239 253
112. S. Armeanu, M. Krusch, K.M. Baltz, T.S. Weiss, I. Smirnow, and A. Steinle Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma Clin Cancer Res 14 2008 3520 3528
113. S. Krieg, and E. Ullrich Novel immune modulators used in hematology: impact on NK cells Front Immunol 3 2012 388
114. A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood 113 2009 6120 6127
115. A. Lundqvist, M. Berg, A. Smith, and R.W. Childs Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells J Cancer 2 2011 383 385